Form 4: 89bio CFO's Equity Changes Amid Roche Merger

89bio's Chief Financial Officer, Ryan Martins, reported significant equity transactions, including RSU settlement and disposal of shares and options, as part of the company's acquisition by Roche Holdings.

Summary

• Ryan Martins, Chief Financial Officer of 89bio, Inc. (ETNB), reported changes in his beneficial ownership of company securities.
• Acquired 35,000 shares of common stock through the settlement of performance-based restricted stock units (RSUs) granted under the Company's Amended and Restated 2019 Equity Incentive Plan.
• Disposed of 374,295 shares of common stock and various stock options due to the completion of the merger of 89bio, Inc. with Bluefin Merger Subsidiary, Inc., a wholly-owned subsidiary of Roche Holdings, Inc.
• The merger involved a tender offer where each outstanding share of 89bio common stock was cancelled in exchange for $14.50 per share in cash, plus one non-tradeable contingent value right (CVR) representing the right to receive up to an aggregate of $6.00 per share upon achievement of specified milestones.
• Outstanding restricted stock units and performance-based restricted stock units became fully vested and were cancelled in exchange for the merger consideration (cash + CVR).
• Outstanding stock options became fully vested and exercisable immediately prior to the merger's effective time, then were cancelled and converted into the right to receive cash (Closing Amount minus exercise price) plus one CVR per share, or only CVRs for certain 'Out of the Money Options' (exercise price between $14.50 and $20.50), or cancelled without payment if the exercise price was equal to or greater than $20.50.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for 89bio shareholders due to the acquisition by Roche, offering a cash premium and potential future upside via CVRs. For the reporting person, it represents a significant liquidity event and vesting of equity awards. However, the company ceases to exist as an independent entity.

Positives

• Performance-based restricted stock units (RSUs) held by the CFO vested and settled, converting into shares.
• The merger provided a liquidity event for shareholders, including the CFO, with a cash component of $14.50 per share and potential additional value through Contingent Value Rights (CVRs) up to $6.00 per share.
• All outstanding stock options became fully vested and exercisable as a result of the merger, allowing for their conversion into cash and CVRs (subject to exercise price conditions).

Negatives

• 89bio, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Roche Holdings, Inc.
• Some stock options with an exercise price equal to or greater than $20.50 were cancelled without any payment.

Future Outlook

The future outlook for 89bio, Inc. as an independent entity is concluded as it has become a wholly-owned subsidiary of Roche Holdings, Inc. The future value for former shareholders depends on the achievement of milestones related to the Contingent Value Rights (CVRs), which could provide up to an additional $6.00 per share.

Industry Context

This acquisition by Roche Holdings, Inc. of 89bio, Inc. reflects ongoing consolidation within the biotechnology and pharmaceutical sectors, where larger players seek to acquire innovative pipelines or established assets to bolster their portfolios. The use of Contingent Value Rights (CVRs) is a common mechanism in biotech M&A to bridge valuation gaps and share future development risks/rewards, particularly for assets in clinical development.

Comparison to Industry Standards

• The use of a cash component ($14.50 per share) combined with Contingent Value Rights (CVRs) (up to $6.00 per share) is a standard practice in biotech acquisitions, especially when the target company has pipeline assets with future milestones.
• This structure is similar to other recent biotech M&A deals where the acquiring company aims to mitigate risk associated with clinical development outcomes while offering potential upside to target shareholders.
• For example, similar CVR structures have been seen in deals like Merck's acquisition of Acceleron Pharma or Bristol Myers Squibb's acquisition of MyoKardia, where milestone payments were tied to regulatory approvals or sales targets.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing liquidity and potential future upside.
• Employees (including Ryan Martins): Equity awards (RSUs, options) vested and converted as part of the merger, providing a liquidity event. Future employment status and compensation structure would be under Roche.
• Company (89bio, Inc.): Ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Roche Holdings, Inc.

Next Steps

• Achievement of specified milestones for CVR payments.
• Integration of 89bio into Roche Holdings, Inc.

Key Dates

Keywords

89bio, ETNB, Roche Holdings, Merger, Acquisition, Form 4, Insider Transaction, Equity Incentive Plan, Restricted Stock Units, Stock Options, Contingent Value Rights, CFO, Ryan Martins